Denali Therapeutics initiates Buy as Avlayah sales beat expectations and pipeline advances toward 2027 approval.

Denali Therapeutics received a Buy rating following strong Q3 Avlayah sales of $17.8M, surpassing guidance, with Q4 expected to grow over 65%. The company’s DNL126 drug for Sanfilippo A is on track for accelerated approval in 2027, leveraging a proven commercial strategy. With about $1 billion in cash to fund operations through 2029 and key assets supporting its valuation, Denali is positioned as a commercial-stage biotech with promising growth potential.

Denali Therapeutics shares trade at USD 19.25 on Pluang as of Nov 13, 2026, 20:42 WIB, up 1.91% for the day. The stock shows strong investor interest with 100% buy orders and a market cap of $3.03 billion. Its 52-week price range is between $16.02 and $27.21, reflecting notable volatility in the health sector.